PMID- 34006273
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20231111
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 21
IP  - 1
DP  - 2021 May 18
TI  - Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty 
      liver disease in type 2 diabetic patients.
PG  - 100
LID - 10.1186/s12902-021-00762-1 [doi]
LID - 100
AB  - BACKGROUND: It is widely acknowledged that nonalcoholic fatty liver disease 
      (NAFLD) and type 2 diabetes mellitus(T2DM) are all chronic metabolic diseases. 
      The objective of this study is to retrospectively probe the association between 
      the 25-hydroxyvitamin D (25-(OH)D) and NAFLD in type 2 diabetic patients. 
      METHODS: Three hundred thirty-nine T2DM patients participated in this research 
      and from November 2018 to September 2019 and were divided into simple T2DM group 
      (108 cases) and T2DM with NAFLD group (231 cases) in conformity with abdominal 
      ultrasound diagnosis. The NAFLD fibrosis score (NFS) >/=0.676 was defined as 
      progressive liver fibrosis.231 T2DM with NAFLD patients were categorized into two 
      subgroups: progressive liver fibrosis subgroup (48 cases) and without progressive 
      liver fibrosis subgroup (183 cases). RESULTS: The prevalence of NAFLD by 
      Abdominal ultrasonography was 68%.The results indicated that the levels of 
      25-(OH) D were significantly lower in T2DM with NAFLD group than that in simple 
      T2DM group(P < 0.01). The levels of 25-(OH) D were significantly lower in 
      progressive liver fibrosis subgroup than that in patients without progressive 
      liver fibrosis and simple T2DM,and 25-(OH) D levels were lower in without 
      progressive liver fibrosis subgroup than that in simple T2DM group(p < 0.01 or 
      p < 0.05). Multivariate logistic regression analysis showed that levels of 
      25-(OH) D were negative correlation with risk of NAFLD and progressive liver 
      fibrosis(p = 0.011、p = 0.044,respectively). CONCLUSIONS: we could come to a 
      conclusion that low levels of 25-(OH) D was a risk factor for NAFLD and 
      progressive liver fibrosis in T2DM patients.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Li, Juyi
AU  - Li J
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Ni, Yingqun
AU  - Ni Y
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui University of 
      Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China.
FAU - Liu, Huaizhen
AU  - Liu H
AD  - Department of Endocrinology, Geriatrics Center, The First Affiliated Hospital of 
      Anhui University of Traditional Chinese Medicine, Hefei, 230001, Anhui, China. 
      1140808869@qq.com.
LA  - eng
GR  - 1908085 MH267/Natural Science Foundation of Anhui Province/
PT  - Journal Article
DEP - 20210518
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 1406-16-2 (Vitamin D)
RN  - A288AR3C9H (25-hydroxyvitamin D)
SB  - IM
MH  - Aged
MH  - Diabetes Complications/*blood/pathology
MH  - Diabetes Mellitus, Type 2/*blood/complications
MH  - Female
MH  - Fibrosis
MH  - Humans
MH  - Liver/pathology
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*blood/complications/pathology
MH  - Retrospective Studies
MH  - Vitamin D/*analogs & derivatives/blood
MH  - Vitamin D Deficiency/*complications
PMC - PMC8130335
OTO - NOTNLM
OT  - Type 2 diabetes mellitus;non-alcoholic fatty liver disease;progressive liver 
      fibrosis;25-hydroxyvitamin D
COIS- The authors declare that they have no competing interests.
EDAT- 2021/05/20 06:00
MHDA- 2021/11/23 06:00
PMCR- 2021/05/18
CRDT- 2021/05/19 05:40
PHST- 2021/01/18 00:00 [received]
PHST- 2021/04/29 00:00 [accepted]
PHST- 2021/05/19 05:40 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2021/05/18 00:00 [pmc-release]
AID - 10.1186/s12902-021-00762-1 [pii]
AID - 762 [pii]
AID - 10.1186/s12902-021-00762-1 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2021 May 18;21(1):100. doi: 10.1186/s12902-021-00762-1.